CoverageForm 410-K10-Q8-K13D13G13F

BIOA Bioage Labs, Inc. - 8-K

Filed Mar 24, 2026. See issuer overview · financials · original on SEC.gov ↗
Accession
0001193125-26-120864
2.027.019.01

Item 2.02 - Results of Operations and Financial Condition

Earnings press release item. The actual results are typically in Exhibit 99.1 - fetch may not have completed.

Item 2.02 Results of Operations and Financial Condition.

On March 24, 2026, BioAge Labs, Inc. (the “ Company ”) issued a press release announcing its financial results for the year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01 - Regulation FD Disclosure

142 words

Item 7.01 Regulation FD Disclosure

The Company has also updated its corporate deck, which is available in the “Investors” portion of the Company’s website at https://ir.bioagelabs.com/.

The information in Item 2.02 and this Item 7.01, including Exhibit 99.1 attached to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “ Securities Act ”). The information contained in Item 2.02, this Item 7.01, and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 - Financial Statements and Exhibits

35 words

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.

Description

99.1

Press release issued by BioAge Labs, Inc. dated March 24, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).